The State of Weight-Loss Drugs

NVIDIA has been the belle of the quarterly earnings ball for quite some time. Investors have been waiting to see how much NIVIDA beat earnings estimates. Even though earnings did beat expectations, the market reaction was “meh”. The gang breaks down NVIDIA’s earnings and investig ...  Show more

The market is buzzing with rumors of companies interested in buying Paypal. We look into whether there’s fire behind the smoke. We also cover earnings from Axon and Cava. Travis Hoium, Lou Whiteman, and Rachel Warren discuss: - Potential buyers for PayPal - Axon earnings - Cava E ...  Show more

This time, we have a very special episode I recorded with my close friend Kevin Rose in person at his house. We trade our latest discoveries, and I think it’s one of our best. Tons o ...

Dr. Marty Makary, a renowned surgeon and professor at Johns Hopkins, public health expert, and a two-time New York Times bestselling author, joins Scott to discuss his latest book, Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health. They go over topics inc ...  Show more

Shares in Eli Lilly surged on Friday  after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what’s already one of the fastest growing markets in medicine. Shares of the drug’s originator Chugai ...  Show more

David Senra is the host of the Founders podcast. For the past nine years, David has intensely studied the life and work of hundre ...